Steven Croley
Psychiatry · Lexington, KYNPI 1265559272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $124,893 of the $150,701 with a category attached, or 82.9%. Supernus Pharmaceuticals, Inc. accounts for 70.5% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $40,361, 2.5 times the $15,846 reported in 2019. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $322.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$106K
- Ironshore Pharmaceuticals Inc.$36K
- AbbVie$6K
- Johnson & Johnson$535
- Corium, LLC$310
- Tris Pharma Inc$249
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$124,89383%
- Travel & lodging$18,39312%
- Food & beverage$7,4095%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 219 | $106,239 |
| Ironshore Pharmaceuticals Inc. | 87 | $36,344 |
| AbbVie(2 entities) | 52 | $5,895 |
| Johnson & Johnson | 16 | $535 |
| Corium, LLC | 18 | $310 |
| Tris Pharma Inc | 18 | $249 |
| Neurocrine Biosciences, Inc. | 8 | $236 |
| Sunovion Pharmaceuticals Inc. | 11 | $220 |
| Otsuka America Pharmaceutical, Inc. | 7 | $108 |
| Neuronetics, Inc. | 3 | $95 |
| Avanir Pharmaceuticals, Inc. | 5 | $88 |
| Collegium Pharmaceutical, Inc. | 4 | $86 |
| Neos Therapeutics, LP | 5 | $73 |
| Lundbeck LLC | 4 | $61 |
| Bausch Health US, LLC | 3 | $39 |
| Shire North American Group Inc | 2 | $34 |
| Vertical Pharmaceuticals, LLC | 2 | $28 |
| Lilly USA, LLC | 1 | $18 |
| Indivior Inc. | 1 | $16 |
| Rhodes Pharmaceuticals L.p. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$100,558
- JORNAY PM$20,977
- Jornay PM 20mg capsules (Bottle of 100)$14,315
- VRAYLAR$5,480
- SPRAVATO$232
- INGREZZA$118
- INVEGA SUSTENNA$112
How this compares
$150,701 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 26 | $88,735 |
| Aripiprazole | 319 | $50,916 |
| VraylarCariprazine Hcl | 34 | $47,470 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 58 | $17,828 |
| Ziprasidone Hcl | 60 | $10,163 |
| Divalproex Sodium ErDivalproex Sodium | 71 | $9,855 |
| Lurasidone Hcl | 31 | $8,944 |
| TrintellixVortioxetine Hydrobromide | 18 | $8,585 |
| Paliperidone ErPaliperidone | 43 | $7,268 |
| Oxcarbazepine | 101 | $5,831 |
| MyrbetriqMirabegron | 12 | $5,493 |
| Quetiapine Fumarate | 181 | $5,032 |
| Clozapine | 34 | $4,134 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 148 | $3,784 |
| Risperidone | 237 | $3,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $535 | $88,73526 claims |
| AbbVieVraylar | $5,895 | $47,47034 claims |
| Lilly USA, LLCOlanzapine | $18 | $3,07266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Lexington
- Mark WrightLexington$637K
- Jacob BishopLexington$56K
- Andrew CooleyLexington$47K
- Syed RizviLexington$17K
- Michelle LofwallLexington$11K
- Saeed HamidLexington$10K
- Getulio TovarLexington$5K
- Brian KeltyLexington$4K
- Andre FernandezLexington$4K
- Carmen PintoElizabethtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.